Monashee Investment Management LLC Takes Position in Immunome, Inc. $IMNM

Monashee Investment Management LLC bought a new stake in Immunome, Inc. (NASDAQ:IMNM) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 274,861 shares of the company’s stock, valued at approximately $5,904,000. Immunome comprises about 3.3% of Monashee Investment Management LLC’s investment portfolio, making the stock its 12th largest holding.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Nuveen LLC lifted its stake in shares of Immunome by 16.5% in the 4th quarter. Nuveen LLC now owns 169,346 shares of the company’s stock valued at $3,638,000 after acquiring an additional 24,002 shares during the last quarter. Primecap Management Co. CA raised its position in Immunome by 55.2% during the 4th quarter. Primecap Management Co. CA now owns 4,685,441 shares of the company’s stock valued at $100,643,000 after purchasing an additional 1,667,432 shares during the last quarter. T3 Companies LLC bought a new position in Immunome during the 4th quarter valued at approximately $264,000. Deutsche Bank AG raised its position in Immunome by 25.1% during the 4th quarter. Deutsche Bank AG now owns 76,242 shares of the company’s stock valued at $1,638,000 after purchasing an additional 15,291 shares during the last quarter. Finally, Erste Asset Management GmbH bought a new position in Immunome during the 4th quarter valued at approximately $1,123,000. Institutional investors own 44.58% of the company’s stock.

Immunome Price Performance

IMNM opened at $18.36 on Friday. Immunome, Inc. has a one year low of $7.96 and a one year high of $27.65. The firm has a market capitalization of $2.08 billion, a price-to-earnings ratio of -7.71 and a beta of 2.04. The business has a 50 day simple moving average of $21.85 and a two-hundred day simple moving average of $21.71.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.12. As a group, sell-side analysts expect that Immunome, Inc. will post -2.06 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Leerink Partners lowered their price target on Immunome from $37.00 to $33.00 and set an “outperform” rating for the company in a research report on Friday, May 15th. Craig Hallum upped their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Truist Financial upped their price target on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, May 28th. Wall Street Zen lowered Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $40.00 price target on shares of Immunome in a research report on Wednesday, May 13th. Twelve investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.17.

Insider Transactions at Immunome

In other news, insider Jack Higgins sold 9,438 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total value of $204,238.32. Following the completion of the transaction, the insider owned 22,000 shares of the company’s stock, valued at approximately $476,080. This represents a 30.02% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Max Rosett sold 65,000 shares of the stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.92, for a total value of $1,424,800.00. Following the completion of the transaction, the chief financial officer directly owned 54,037 shares of the company’s stock, valued at $1,184,491.04. This represents a 54.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 139,438 shares of company stock worth $2,964,664 over the last 90 days. 7.21% of the stock is currently owned by insiders.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.